<DOC>
	<DOCNO>NCT00080951</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , fluorouracil , leucovorin , oxaliplatin , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy first-line therapy treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan , Fluorouracil , Leucovorin , Oxaliplatin First-Line Therapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine tumor response rate patient metastatic colorectal cancer treat irinotecan , fluorouracil , leucovorin calcium , oxaliplatin first-line treatment . Secondary - Determine time tumor progression , time treatment failure , overall survival patient treat regimen . - Determine toxicity regimen patient . - Determine quality life patient treat regimen . - Determine whether UGT1A1 polymorphism relate toxicity ( especially leukopenia , diarrhea , neutropenia ) response patient treat regimen . OUTLINE : This multicenter study . Patients receive irinotecan IV 90 minute oxaliplatin IV 2 hour day 1 leucovorin calcium IV fluorouracil IV 90 minute day 2-5 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Quality life assess baseline , chemotherapy course , end treatment . Patients follow every 3 month 5 year registration .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis colorectal adenocarcinoma Metastatic disease Not curable surgery amenable radiotherapy curative intent Measurable disease Patients lesions measure ≥ 1 cm &lt; 2 cm must use spiral CT scan pre posttreatment tumor assessments No known CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ≤ 5 time upper limit normal ( ULN ) Bilirubin ≤ 0.5 mg/dL ULN Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 60 mL/min Cardiovascular No unstable angina No symptomatic congestive heart failure No serious uncontrolled cardiac arrhythmia Pulmonary No prior clinical diagnosis interstitial lung disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled infection No concurrent serious illness No preexisting paraesthesias/dysesthesias ≥ grade 2 would interfere function No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat noninvasive carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent sargramostim ( GMCSF ) Chemotherapy At least 6 month since prior adjuvant chemotherapy No prior fluorouracil advanced colorectal cancer No prior adjuvant oxaliplatin No prior adjuvant irinotecan Endocrine therapy Not specify Radiotherapy No prior radiotherapy &gt; 25 % bone marrow Surgery At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>